THE TRUTH ABOUT: Biontech - The Untold Story

Gotistobart Nearly Doubled Median Survival Versus Chemotherapy in 87 Patient Lung Cancer Trial Stage, Pivotal Data Pending

Gotistobart reached 18.5 months median survival versus 10.0 months for chemotherapy in 87 previously treated squamous lung cancer patients. Pivotal data pending.

Medical Daily · Sep 14

BioNTech Halted a Cancer Vaccine Trial, and Genentech Says There Were More Deaths in the Vaccine Group

BioNTech terminated a Phase 2 mRNA cancer vaccine trial in colorectal cancer after monitors found a survival imbalance between the two arms.

Medical Daily · Sep 1

Updated COVID Shots Matched to the XFG Variant Reach Pharmacies While Federal Eligibility Guidance Remains Unsettled

FDA approved updated 2026-2027 COVID vaccines targeting XFG. Here is who qualifies, what insurance covers, and what guidance is still missing.

Medical Daily · Aug 28

BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides

BioNTech shares sank yesterday as disappointing Q1 results prompted layoffs. But long-term investors still have ample reasons to load up on BNTX stock today.

Barchart · May 6

A Grim Diagnosis, but New Science Is Rewriting the Story of Pancreatic Cancer

The day draws nearer when it is no longer "a death sentence."

Reason · Apr 21

BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here?

BioNTech shares are crashing as the company posted a disappointing Q4 release and announced cofounders departure by the end of 2026. Here’s why BNTX stock is still worth buying today.

Barchart · Mar 10

Life-saving therapies are being delayed as research funding dries up

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

The Guardian - UK · Jan 9

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Benzinga · Dec 9, 2025

Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?

Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?

Barchart · Nov 20, 2025

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BioNTech SE (NASDAQ:BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings of 75 cents per share.

Benzinga · Nov 3, 2025